Przejdź do zawartości
Merck

Y0000009

Fluphenazine enantate

European Pharmacopoeia (EP) Reference Standard

Synonim(y):

2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl heptanoate

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

100 MG

506,00 zł

506,00 zł


Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności

Zamów zamówienie zbiorcze

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):
C29H38F3N3O2S
Numer CAS:
Masa cząsteczkowa:
549.69
UNSPSC Code:
41116107
NACRES:
NA.24

Przejdź do

Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc

SMILES string

FC(F)(F)c1cc2c(cc1)Sc3c(cccc3)N2CCCN4CCN(CC4)CCOC(=O)CCCCCC

InChI

1S/C29H38F3N3O2S/c1-2-3-4-5-11-28(36)37-21-20-34-18-16-33(17-19-34)14-8-15-35-24-9-6-7-10-26(24)38-27-13-12-23(22-25(27)35)29(30,31)32/h6-7,9-10,12-13,22H,2-5,8,11,14-21H2,1H3

InChI key

LRWSFOSWNAQHHW-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

fluphenazine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 4

Ta pozycja
Y0000298Y0000299F0260000
manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

format

neat

format

neat

format

neat

format

neat

API family

fluphenazine

API family

fluphenazine

API family

fluphenazine

API family

fluphenazine

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

-

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluphenazine enantate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.
Ta strona może zawierać tekst przetłumaczony maszynowo.

pictograms

Skull and crossbonesHealth hazard

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral - Repr. 1A

Klasa składowania

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumenty section.

Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

A C Altamura et al.
Psychopharmacology, 87(1), 30-33 (1985-01-01)
Seven outpatients already receiving neuroleptic drugs by depot intramuscular injections were treated in two consecutive 3-week periods with 25 mg fluphenazine doses as enanthate and decanoate esters in a double-blind crossover study. They were assessed for incidence of akinesia, involuntary
Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
G Chouinard et al.
The American journal of psychiatry, 139(3), 312-318 (1982-03-01)
W M Glazer
The Journal of clinical psychiatry, 45(5 Pt 2), 28-35 (1984-05-01)
The risks and benefits associated with depot fluphenazine are reassessed by a review and critique of the literature, with an emphasis on controlled studies comparing depot to oral preparations. Specific gaps in our knowledge are noted and recommendations are made
K Yamada et al.
Pharmacology, 24(3), 147-155 (1982-01-01)
The cataleptic state induced by the depot-type preparations of fluphenazine (FZ) was investigated in mice. Intramuscular injections of FZ-enanthate or FZ-decanoate produced a marked and long-lasting catalepsy, which was antagonized by trihexyphenidyl, biperiden and promethazine but not by l-dopa. These
T P Hogan et al.
Canadian journal of psychiatry. Revue canadienne de psychiatrie, 28(4), 277-281 (1983-06-01)
The authors examined drug prescribing patterns and incidence of side effects in schizophrenic patients who committed suicide as compared with a matched control group. The groups did not differ in type of drug prescribed, though patients in the suicide group

Questions

Reviews

No rating value

Active Filters

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej